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Hemodialytic treatment of patients with either acute or
chronic renal failure has had a dramatic impact on the
mortality rates of these patients. Unfortunately, this
membrane-based therapy is still incomplete renal
replacement, as the mortality and morbidity of these patients
remain unacceptably high. Much progress must be made to
improve the biocompatibility of hemodialysis membranes as
well as their hydraulic and permselective properties to
remove small solutes and ‘middle molecules’ in compact
cartridges. The next directions of development will leverage
materials and mechanical engineering technology, including
microfluidics and nanofabrication, to further improve the
clearance functions of the kidney to replicate glomerular
permselectivity while retaining high rates of hydraulic
permeability. The extension of membrane technology to
biohybrid devices utilizing progenitor/stem cells will be
another substantive advance for renal replacement therapy.
The ability to not only replace solute and water clearance but
also active reabsorptive transport and metabolic activity will
add additional benefit to the therapy of patients suffering
from renal failure. This area of translational research is rich in
creative opportunities to improve the unmet medical needs
of patients with either chronic or acute renal failure.
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The kidney was the first solid organ whose function was
approximated by a machine and a synthetic device. In fact,
renal substitution therapy with dialytic techniques has been
the only successful long-term ex vivo organ substitution
therapy to date. Although chronic dialysis has certainly
changed the prognosis of end-stage renal disease (ESRD), it
has substantial shortcomings resulting in severe morbidity
and high annual mortality rates exceeding 20%. Accordingly,
continuing improvements in hemodialysis (HD) membranes
have occurred to reduce the morbid and mortal consequences
of HD treatments in patients with renal failure (Table 1).
TRADITIONAL MEMBRANES
The idea of the substitution of clearance function of the
kidney to remove small solutes and water is based upon the
concept of dialysis first described by Graham1 utilizing a
semipermeable membrane and concentration gradients
across the membrane for vectorial transport of substances.
Cellulose-based material has been used for this purpose since
the first human HD treatment with collodion tube
membranes.2 Later, the rotating drum dialyzer, consisting
of a long cellophane tube spirally wrapped around a cylinder
that rotated in a stationary dialysate bath, was created by
Kolff and Berk3 and became the first suitable apparatus for
widespread clinical use. This advance was recognized recently
with a Lasker Award presented to Kolff.4 There were several
later designs of dialyzers, including coil and parallel flow
dialyzers, before the widespread use of hollow-fiber dialyzers
as the current formulation for HD treatment.5 The original
development of hollow-fiber dialyzers in the 1960s utilized
regenerated cellulose as the principal membrane material.
Concerns of the bioincompatibility derived from the
hydroxyl groups within the cellulose structure led to the
development of another membrane material, called modified
cellulose, with improved biocompatibility. The hydroxyl
groups in these modified membranes were masked either
by replacing them with other chemical structures, such as
acetyl derivatives, or by bonding with potentially advanta-
geous compounds, such as vitamin E or heparin. The use
of vitamin E-bonded membranes was recently developed
to further improve biocompatibility and minimize HD-
associated oxidant stress,6 thereby modifying the excessive
inflammatory state of ESRD. The relevance of this type of
membrane in improving clinical outcomes in HD is still
awaiting verification.
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Besides improvements in biocompatibility, HD membranes
have been developed to better reproduce the physiologic
process of glomerular ultrafiltration. It has long been
recognized that dialytic membrane clearance was based on
concentration differences rather than convective separation of
small solutes and low molecular weight proteins from large
serum proteins and blood elements. In an attempt to
recapitulate glomerular ultrafiltration and removal of ‘middle
molecules’, synthetic membranes with larger pore sizes and
high water permeability compared to cellulosic membranes
were developed. These so-called ‘high flux’ membranes are
prepared with hydrophobic base materials, including poly-
acrylnitrile, polysulphone, polyarylethersulphone, or poly-
mide, with various hydrophilic components. These have
supplemented cellulosic membranes owing to manufacturing
processes that can mass produce membranes with wide ranges
of hydraulic permeabilities for various treatment modalities.7
Based upon this technology, the main focus of recent
membrane development has been to increase pore size while
sharpening the molecular weight cutoff of high-flux mem-
branes to maximize removal of low molecular weight
proteins. This direction is based upon the idea that removal
of a distinct class of uremic toxins, such as b2-microglobulin,
factor D, leptin, and adrenomedullin, while minimizing the
loss of albumin8 could improve treatment outcomes of
patients with ESRD. Further work has evolved with super-
flux or protein-leaking membranes. These membranes
provide greater clearances for low molecular weight proteins
and small protein-bound solutes, such as homocysteine and
advanced glycation end products, but with significantly
higher loss of albumin than high-flux dialysis membranes.
The overall benefits for patients on chronic HD still require
more extensive evaluation.9 Nonmembrane-related determi-
nants of dialyzer performance, including fiber bundle
configuration, spacing, and sterilization techniques, are also
deserving of further study.10
INNOVATIVE MEMBRANES
Three areas of research in the development and engineering
of truly novel hemodiafiltration membranes may provide
new ways to improve and/or miniaturize HD processes.
Edward Leonard’s group has published two recent articles
exploring membraneless dialysis.11,12 This research has
cleverly exploited microfluidic principles to achieve dialysis
without blood–membrane contact. For sufficiently low
Reynolds numbers, it is possible to introduce parallel flows
of miscible liquids in direct contact with each other, without
significant convective mixing of the two liquids. The two
liquids may be physically separated again at a distant point.
Diffusive transport of solutes, however, can take place from
one fluid path to the other. A small stream of blood jacketed
by concurrently flowing streams of dialysate can be
conceived. Particulates in blood continue along the stream-
lines of liquid flow, but solutes diffuse from blood to
dialysate according to their diffusive mobilities, generally in
inverse proportion to their molecular weight. Leonard’s
group has examined behavior of blood and proteins in a
model system with promising results. They acknowledge that
a two-stage separation is necessary, as macromolecules
equilibrate with recirculated dialysate, regardless of their
molecular weight. An alternate description of the technique
would be that a water jacket provides a layer of biocompat-
ibility between blood and membrane – possibly distant from
the patient. They have shown data from a prototype
separator, and further work from this group is anticipated.
Nissenson and colleagues have proposed a novel renal
replacement device that they have termed the ‘human
nephron filter’.13 They describe a two-stage filtration device
roughly analogous to the glomerulus and the tubule. The
glomerular membrane (‘G membrane’) is a conventional
hemofiltration membrane that passes small solutes and
retains macromolecules and cells. The driving force for
ultrafiltration is not specified and might be pumps or arterial
pressure. The tubular membrane (‘T membrane’) is a
synthetic membrane incorporating synthetic ion and aqua-
porin channels. The T membrane in theory allows reabsorp-
tion of salt and water while other solutes are progressively
concentrated in the ultrafiltrate stream. The ion channels
appear to be entirely synthetic macromolecular pores. A
recent commentary refers to computer modeling of solute
transport across the two-membrane system and provides
estimates of clearance provided by their model system. The
concept is exciting as it presents the possibility of dialysis-free
renal replacement.
The motive force driving reabsorption across the T
membrane, however, is not discussed in detail. It is unclear
from their brief review whether transport across the T
membrane is solely driven by hydrostatic pressure, similar to
reverse osmosis water purification processes, as no mecha-
nism for active transport is described. Typical reverse osmosis
processes require high transmembrane pressures and generate
modest ultrafiltration rates. If their secondary separation
process does resemble a modified reverse osmosis process,
this formulation will place stringent requirements on pump
energy consumption and membrane burst strength.
Our laboratory has focused its efforts on novel membrane
technology for ultrafiltration to better replicate glomerular
Table 1 | Improvements in hemodialysis membranes
Traditional membranes
1. Biocompatibility: New materials and chemical modifications of side
chains
2. Refining pore dimensions to enhance hydraulic permeability and
middle molecule clearance
Innovative membranes
1. Microfluidics and membraneless systems
2. Nanofabrication with synthetic channels
3. Nanofabricated silicon membranes with slit pores
Living membranes
1. Endothelial cell-lined membranes for hemocompatibility and
durability
2. Tubule cell-lined membranes for active transport and metabolic
activities
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filtration processes. The filtration barrier in the kidney has
been extensively studied, and overviews of anatomy and
theoretical modeling have been published.14,15 The filtration
barrier in the kidney is widely considered to be a trilaminate
structure, including an endothelial cell layer, a specialized
glomerular basement membrane, and an elaborate epithelial
layer bearing a specialized cell–cell junction called the
glomerular slit diaphragm. The relative contributions of
each layer of the filtration structure continue to be debated,16
but there are long-established histologic correlates between
disruption of the cell–cell junction between glomerular
epithelial cells (‘podocytes’) and the appearance of protein
in the urine. Recent advances in molecular biology have
further characterized the glomerular slit diaphragm, and
heritable mutations in the proteins that form the slit
diaphragm and genetic knockout experiments in animal
models have demonstrated that the slit diaphragm is
necessary for solute retention in the kidney’s filter. Con-
vergence between nanofluidic modeling and observed
behavior of the glomerular filter suggest that salient
functional features may be captured by a slit-shaped pore
with specific geometric and electrostatic features.
Current polymer membranes used in dialysis and ultra-
filtration have been extensively studied. The pores in such
membranes are formed by extrusion and solvent-casting
techniques. The geometry and surface chemistry of the pores
arise from the chemistry of the polymers and the fluid
dynamics of the casting process. In general, the hollow-fiber
membranes are fairly thick or employ a multilayer scaffold
for mechanical support, and have a distribution of pore sizes
rather than a regular array of uniform pores. Pores in
conventional polymeric membranes tend to be either roughly
cylindrical, have a round orifice terminating a larger channel,
or have a structure resembling an open-cell sponge. Extensive
description of porous structures used in commercial ultra-
filtration and microfiltration have been published.17,18 It is
not clear that any of these structures provide optimal
geometries for membrane filtration, for two reasons. First,
a wide dispersion in pore sizes within a membrane leads to
imperfect retention of molecules larger than the mean pore
size of the membrane. This problem is remedied in practice
by engineering the mean pore size of the membrane to be
sufficiently small that negligibly few pores are so large as to
allow passage of a solute above the desired molecular weight
cutoff of the membrane. This solution, however, has the
undesired effect of reducing the mean pore size in the
membrane and thus reducing the hydraulic permeability of
the membrane. Engineering narrower pore size distributions
ameliorates this dilemma, allowing sharper transitions from
passage to retention and maximizing the mean pore size of
the membrane.
Second, the round shape of conventional pores dictates a
fourth-power dependence of hydraulic permeability on pore
radius r: Q/DP¼ pr4/8mL, where Q denotes volumetric flow,
P is hydrostatic pressure, r is the radius of the pore, m is
viscosity, and L is the length of the pore, which may or may
not be the same as the thickness of the membrane. A pore
that is slit-shaped allows steric hindrance to solute passage
dictated by the smallest critical dimension of the pore, while
increasing hydraulic permeability by a factor of the long
dimension of the pore w: Q/DP¼wh3/12mL, where w is the
long dimension of the slit, h is the thickness of the slit, and L
is again the length of the pore. Consequently, it might be
predicted that filtration structures with parallel slit-shaped
pores might have superior performance when compared to
structures with round pores. With that in mind, it is
interesting but speculative to note that natural selection has
produced filtration structures with elongated, slit-shaped
geometries in the kidney, in the beaks of filter-feeding birds
such as the flamingo, and in the baleen of filter-feeding
whales.
Turning from steric hindrance to electrostatic effects, it
has long been argued that the glomerular filtration barrier
imposes an electrostatic restriction on solute passage.15 This
function has been variously attributed to the proteins within
the slit diaphragm, the glomerular basement membrane, and
the glycocalyx of the glomerular endothelial cell.19 At
physiologic pH, many materials, such as glass, have an
anionic surface charge, which can be neutralized at lower pH
or possibly increased at higher pH. The net charge density on
a microfluidic substrate in contact with an aqueous solution
gives rise to an electrical double layer in the aqueous solution.
This shielding layer is commonly known as the Debye layer or
electrical double layer. For nanometer-scale pores, the
thickness of the electrical double layer is in the same order
of magnitude as the pore size itself and can contribute to the
rejection of charged solutes by the pore.
These first principle predictions suggest strongly that a
membrane composed of slit-shaped pores can separately
regulate steric and electrostatic hindrance with extremely
high hydraulic permeability. These insights into structure–-
function correlates in the kidney have motivated the design
and construction of a silicon membrane with slit-shaped
pores, the dimensions of which approximate the dimensions
of the glomerular slit diaphragm. Testing and characteriza-
tion of these membranes constitute a unique engineering
challenge and opportunity as they allow for prediction and
measurement of performance across length scales spanning
several orders of magnitude.
Silicon membranes with 10–100 nm 45 mm slit pores
were designed and fabricated at The Cleveland Clinic
Foundation and Case Western Reserve University. Our
laboratory performed initial hydraulic characterization of
these membranes (unpublished data). Silicon chips bearing
1 1 mm arrays of approximately 104 slit pores were
fabricated via sacrificial layer techniques (Figure 1). The
pore structure is defined by deposition and patterning of a
polysilicon film on the silicon wafer. The critical submicron
pore dimension is defined by the thickness of a sacrificial
SiO2 layer, which can be grown with unprecedented control
to within 71 nm. The oxide layer is etched away in the final
processing step to create the porous polysilicon membrane.
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Extensive testing of the transport properties of these novel
biomimetic membranes is underway in our laboratory.
Measured hydraulic permeabilities correlated well with
theoretical predictions for flow-through slit-shaped pipes,
also known as Hele–Shaw flows (Figure 2). Preliminary data
provide encouragement that protein permselectivity is
feasible with this technology, paving the way for a glomerular
analog with high hydraulic permeability and strict size and
charge-dependent rejection of solutes.
LIVING MEMBRANES
As progress moves toward hemodiafiltration with wearable or
implantable devices, a major limitation of current membrane
technology is diminution of filtration rate owing to protein
deposition on the membrane and thrombotic occlusion of
the hollow fibers. These problems reduce the durability of the
filtration membrane. The potential for endothelial cell-seeded
conduits along filtration surfaces may provide hemocompati-
bility and hemofiltration in vivo for these longer term
applications.20 Microfabricated capillary networks with
microelectromechanical system techniques and endothelial
attachment and growth have made substantive advances
recently.21 The use of autologous circulating endothelial cell
progenitors provides a histocompatible cell source for device
fabrication. The clinical development of this approach is still
years from application.
The technologic strategies detailed above have focused
predominantly on the first steps of the excretory function of
the kidney. The use of current or future membrane
technology directed only towards small solute and fluid
removal in patients with either acute or chronic renal failure
will continue to result in incomplete renal substitution
therapy. The extension of the lost reclamation, metabolic,
and endocrine functions of the kidney depends on the
development and clinical application of living membranes
incorporating renal tubule cells. This approach may add
significant value to the current suboptimal treatments based
on inanimate hemodiafiltration membranes. It depends on
the ability to isolate and expand in culture tubule cells from
adult kidneys,22 which are then grown along the inner surface
of the fibers in a standard hemofiltration cartridge.23 The
high-flux hemofiltration membrane and associated extra-
cellular matrix molecule coating thus act as scaffold and
immune barrier for the cells of the bioartificial tubule. The
ultimate goal of this approach is to replace metabolic activity
of the kidney to improve biologic homeostasis, including
immunologic, cardiovascular, and mineral metabolism. As
important, renal tubule cells may provide a biologic means to
reabsorb selectively a convectively produced ultrafiltrate
when in series with a hemofilter. This resorption process is
critical in maintaining volume homeostasis in a patient with
ESRD requiring 5–10 ml/min of clearance function.
In vitro testing of this renal tubule cell assist device, called
the RAD, demonstrated differentiated active transport
properties, metabolic activities, and endocrine processes
characteristic of the renal tubule.23 This tubule cell cartridge
in series with a conventional hemofilter comprises a
bioartificial kidney that provides filtration, reabsorption,
and metabolic and endocrine activity. Ex vivo animal testing
has borne out the results of this in vitro study. Renal tubule
cell assist devices containing either porcine or human cells
have been evaluated on uremic dogs, following bilateral
nephrectomy.24,25 RAD treatment of these animals resulted in
improvements in multiple physiological parameters com-
pared to treatments with cell-free sham RAD controls.
Furthermore, in canine and porcine models of acute renal
failure (ARF) with septic shock, RAD treatment was shown
to modulate plasma cytokine levels, maintain better cardio-
vascular performance, and increase survival times.26–28
These preclinical animal data led to a Food and Drug
Administration-approved Phase I/II clinical trial on 10
critically ill patients with ARF and multiple organ failure
(and predicted hospital mortality rates averaging above 85%)
receiving continuous venovenous hemofiltration.29 The
devices used in this study were seeded with human kidney
cells isolated from organs donated for cadaveric transplanta-
tion but which could not be used for this purpose owing to
anatomic or fibrotic defects. The results demonstrated that
RAD treatment can be safely delivered under study protocol
Single
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Figure 1 | Photomicrograph of silicon nanopore membrane.
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Figure 2 | Hydraulic permeability of silicon nanopore membranes
(SNMs). Hydraulic permeability of SNMs to phosphate-buffered
saline was measured for pore sizes from 8 nm 45 mm to
100 nm 45 mm (solid squares). Experimental data agreed well with
predicted behavior for Hele–Shaw liquid flow (dashed line). Hydraulic
permeability for two conventional polymer membranes is plotted on
the Y axis for comparison.
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guidelines in this critically ill patient population for up to
24 h and that the device retains viability, durability, and
functionality throughout. Furthermore, six of the 10 treated
patients survived past a 30-day primary efficacy end point.
Supported by these encouraging initial clinical results, a
Phase II clinical trial is currently under way. The early results
have been equally compelling as the Phase I/II trial results. In
a randomized, multicenter trial, renal cell therapy improved
the 28-day mortality rate from 61% in the conventional
hemofiltration-treated control group to 33% in the RAD-
treated group (preliminary data communicated by J Tumlin).
In an extension of this approach to chronic renal failure, an
evaluation of renal tubule cell therapy in an exploratory
Phase I/II trial in ESRD patients on chronic HD is planned to
begin in early 2006. This trial will focus on safety issues as
well as assess the influence of short-term cell therapy on the
key biomarkers, C-reactive protein and interleukin-6, as
surrogates of the proinflammatory state of ESRD. This
protocol will test the hypothesis as to whether the excessive
proinflammatory state of ESRD, the root cause of accelerated
atherosclerosis, may be owing to renal tubule cell loss rather
than a decline in renal clearance function.
SUMMARY
Future improvements of HD membranes will most likely
leverage material and mechanical engineering developments
related to microfluidics and nanofabrication technologies to
refine and miniaturize current membrane fabrication. The
development of biohybrid devices utilizing hemodiafiltration
membranes and progenitor/stem cell sources will also
improve current biocompatibility limitations while providing
more complete renal function replacement. This exciting new
work will continue to advance the goal of improving the well-
being and clinical outcomes of patients with renal failure,
who currently receive relatively incomplete and nonphysio-
logic renal substitution therapy. It is a formidable but
scientifically challenging task.
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